Yahoo Finance analysis indicates that despite Madrigal Pharmaceuticals (NASDAQ: MDGL) stock price falling over 7% this year, institutional investors are still heavily buying into the company, holding over 95% of its outstanding shares. Among them, Baker Brothers Advisors, Janus Henderson Group, and RTW Investments hold 2.14 million, 2.10 million, and 1.99 million shares, respectively. The analysis suggests that institutional investors are optimistic about the sales growth potential of the company's first approved drug, Rezdiffra (Q2 sales of $364.3 million, a 71% year-over-year increase), and its attractiveness as an acquisition target for large pharmaceutical companies. However, the company's Q2 loss per share was $1.99, higher than $1.50 in the same period last year.